BLA for lead candidate, inebilizumab (anti-CD19 mAb), is under FDA review for the treatment of neuromyelitis optica spectrum disorder (NMOSD); PDUFA date June 11, 2020. VIB7734, anti-ILT7 mAb, Phase 1b interim data 1H20. Ph 2 trials ongoing for VIB4920 (Anti-CD40L-Tn3 Fusion Protein) in Sjogren's Syndrome and kidney transplant rejection. Additional trials with inebilizumab expected to initiate in 2020, including myasthenia gravis and IgG4-related disease.
US - South Atlantic
Phase III, Phase l or ll
One MedImmune Way
Fifth Floor, Suite Area Two
Gaithersburg, MD 20878
Top 10 Holders of Viela Bio, Inc.
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by